Cybin Completes Its 51st Pre-Clinical Study of Psychedelic Compounds for Mental Health Treatment Jun 30, 2021
Traction for Psychedelics: First Psychedelics ETF Comes to the US as Bills Move Forward in California, Texas, and New… Jun 9, 2021
Cybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related… Jun 8, 2021
Cybin Announces Sponsorship of a Kernel Flow Feasibility Study to Measure Ketamine’s Psychedelic Effects on Cerebral… Jun 1, 2021
Cybin Files an International Patent Application Further Strengthening its Psychedelic Derivative Drug Development… May 26, 2021
Cybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms May 20, 2021
